Table 3.

The descriptive data, clinical parameters comparison between responders and non-responders group

	Non-Responders	Responders	Test value	P- value	Sig.
	No. = 16	No. = 50
Age
Mean ± SD	62.75 ± 5.05	62.52 ± 6.17	0.135•	0.893	NS
Range	53–69	52–74
Gender
Male	12 (75.0%)	26 (52.0%)	2.625*	0.105	NS
Female	4 (25.0%)	24 (48.0%)
BMI
Mean ± SD	31.94 ± 4.82	30.54 ± 4.46	1.069•	0.289	NS
Range	26–43	24–46
Diabetes
Yes	10 (62.5%)	29 (58.0%)	0.102*	0.750	NS
HTN
Yes	9 (56.2%)	34 (68.0%)	0.737*	0.391	NS
CKD
eGFR > 60	7 (43.8%)	50 (100%)	32.602*	< 0.001	HS
eGFR30-60	9 (56.2%)	0 (0.0%)
Cardiomyopathy
DCM	3 (18.8%)	31 (62.0%)	9.078*	0.003	HS
ICM	13 (81.2%)	19 (38.0%)
ACEI
Yes	7 (43.8%)	43 (86.0%)	11.781*	0.001	HS
ARNI
Yes	0 (0.0%)	7 (14.0%)	2.506*	0.113	NS
BB
Yes	16 (100.0%)	50 (100.0%)	–	–	–
Diuretics
Yes	16 (100.0%)	47 (94.0%)	1.006*	0.316	NS
MRAs
Yes	4 (25.0%)	40 (80.0%)	16.500*	< 0.001	HS
SGLT2 inhibitor
Yes	2 (12.5%)	6 (12.0%)	0.003*	0.957	NS
QRS duration (msec)
Mean ± SD	135.00 ± 5.16	152.80 ± 24.25	− 2.901•	0.005	HS
Range	130–140	130–200
Non-Strauss/Strauss
Non-Strauss	10 (62.5%)	26 (52.0%)	0.539*	0.463	NS
Strauss	6 (37.5%)	24 (48.0%)
Range	–	5–15

Body mass index, chronic kidney disease, dilated cardiomyopathy, hypertension, ischemic cardiomyopathy, standard deviation, angiotensin converting enzyme inhibitor, angiotensin receptor neutrilypsin inhibitor, beta-blockers, body mass index, chronic kidney disease, dilated cardiomyopathy, mineralocorticoids receptor antagonists, standard deviation, number. *: Chi-square test; •: Independent t-test